Clinical Trial Results: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results of NUC-3373 in combination with other agents in patients with advanced solid tumors; study status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Classical Hodgkin Lymphoma
• Endometrial Carcinoma
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Msi-h Colorectal Cancer
• Neoplasm Malignant
• Non-small Cell Lung Cancer
• Oesophageal Carcinoma
• Pleural Mesothelioma
• Renal Cell Carcinoma
• Solid Tumor
• Subungual Squamous Cell Carcinoma
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• NUC-3373

Snippet

Sponsor: NuCana plc | Conditions: Advanced Cancer, Advanced Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-07-23